Worldwide Clinical Trials: expanded bioanalytical laboratory
Contract research organization Worldwide Clinical Trials has expanded its early-phase, large-molecule services with a new 15,000-square-foot lab at its Austin, Texas Bioanalytical Center of Excellence. The dedicated lab is expected to offer a forecasted sample analysis scale of about 70,000 annually, increasing to about 200,000 in 2024, across pharmacokinetic (PK), anti-drug antibodies (ADA), and biomarkers.
“We are excited to expand our services to meet the rapid increase in large molecule demands and to better support our sponsors’ unique needs – giving them a competitive advantage to face the bioanalytical revolution head-on,” said Mike Mencer, WCT’s executive vice president and general manager for early phase. “Our expanded capacity is vital to the development of large molecule products, such as vaccines, blood products, and gene and cellular therapies for patients.”
